Advanced search
Start date
Betweenand

In vitro evaluation of Sorafenib and Rapamycin antitumor activity in canine mammary carcinoma metastatic cells

Grant number: 18/17109-9
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): January 01, 2019
Effective date (End): October 31, 2020
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Pathology
Principal researcher:Renee Laufer Amorim
Grantee:Giulia Gumiero Guiraldelli
Home Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Mammary gland tumors are important in Veterinary Medicine due its high incidence in non-castrated female dogs, with most cases being histologically malignant. In addition, this is the most common tumor in women, being the dog a relevant model for the comparative study in humans due its similar clinical and molecular characteristics. The PDGFR pathway has been shown to be extremely important in cancer studies, but there are few studies evaluating this pathway role in canine mammary gland tumors. Thus, this research aims to evaluate the antitumor response of Rapamycin and Sorafenib in metastatic and its primary mammary gland carcinoma cells. For this, we will evaluate the cells before and after treatment with both tyrosine kinase inhibitors using Western Blotting, gene expression, MTT ([3- (4,5-dimethylthiazol-2yl) -2,5-diphenyl tetrazolium bromide] and trypan blue bromide to evaluate the response of the different cells.

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
PRADO, MARIA CAROLINA MANGINI; MACEDO, SOFIA DE ALMEIDA LOSANT; GUIRALDELLI, GIULIA GUMIERO; DE FARIA LAINETTI, PATRICIA; LEIS-FILHO, ANTONIO FERNANDO; KOBAYASHI, PRISCILA EMIKO; LAUFER-AMORIM, RENEE; FONSECA-ALVES, CARLOS EDUARDO. Investigation of the Prognostic Significance of Vasculogenic Mimicry and Its Inhibition by Sorafenib in Canine Mammary Gland Tumors. FRONTIERS IN ONCOLOGY, v. 9, DEC 19 2019. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.